

ASX RELEASE

22 July 2019

## Amplia Therapeutics to Present at 15<sup>th</sup> Bioshares Biotech Summit

Amplia's Therapeutics today announced that the Company will present at the Bioshares Biotech Summit on Friday, July 26<sup>th</sup>, 2019 at 11:50 a.m. in Queenstown, New Zealand.

A copy of the presentation will be released to the market and made available on the Company's website at [www.ampliatx.com](http://www.ampliatx.com) immediately prior to the conference session.

- End -

### For Further Information

John Lambert, CEO

+61 409 525 259

[www.ampliatx.com](http://www.ampliatx.com)

### About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).